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†Department of Chemistry, University of California, Riverside, California; and ‡Verachem, Germantown, MarylandABSTRACT Accurate free-energy calculations provide mechanistic insights into molecular recognition and conformational
equilibrium. In this work, we performed free-energy calculations to study the thermodynamic properties of different states of
molecular systems in their equilibrium basin, and obtained accurate absolute binding free-energy calculations for protein-ligand
binding using a newly developed M2 algorithm. We used a range of Asp-Phe-Gly (DFG)-in/out p38a mitogen-activated protein
kinase inhibitors as our test cases. We also focused on the flexible DFG motif, which is closely connected to kinase activation
and inhibitor binding. Our calculations explain the coexistence of DFG-in and DFG-out states of the loop and reveal different
components (e.g., configurational entropy and enthalpy) that stabilize the apo p38a conformations. To study novel ligand-
binding modes and the key driving forces behind them, we computed the absolute binding free energies of 30 p38a inhibitors,
including analogs with unavailable experimental structures. The calculations revealed multiple stable, complex conformations
and changes in p38a and inhibitor conformations, as well as balance in several energetic terms and configurational entropy
loss. The results provide relevant physics that can aid in designing inhibitors and understanding protein conformational equilib-
rium. Our approach is fast for use with proteins that contain flexible regions for structure-based drug design.INTRODUCTIONMolecular recognition (i.e., the binding of specific mole-
cules by noncovalent interactions) is fundamentally im-
portant in chemistry. Recognition of chemical drugs and
proteins is also important in medicine, and proteins fre-
quently exist in multiple states in their equilibrium basin
when a chemical drug associates to its protein target.
Although experiments provide three-dimensional structures,
they are limited to one static conformation. In addition,
the mechanisms underlying ligand-protein recognition and
dynamical equilibrium can only be addressed by further
theoretical studies. In this study, we used a computational
technique to calculate free energy for an attractive kinase
system to study ligand-protein binding and protein confor-
mational changes. Protein kinases regulate diverse cellular
functions and play a key role in coordinating signal trans-
duction cascades (1). All known protein kinases share the
same tertiary structure, with an N-terminal lobe (N-lobe)
and a C-terminal lobe (C-lobe). These two lobes and parts
of the activation and glycine-rich loop form a binding site
for ATP and kinase inhibitors (Fig. 1 a) (2). Nearly every
eukaryotic protein kinase domain has a conserved Asp-
Phe-Gly (DFG) motif. Flipping of the DFG motif connects
catalytically active and inactive kinases (Fig. 1 b), but the
mechanism of this flip is not precisely detailed. The Asp
from the DFG motif is crucial for catalysis and contacts
with the phosphates of ATP, but the function of the con-
served Phe and Gly is not entirely clear. The movement of
the DFG motif from the in to the out conformation opens
up a hydrophobic pocket between the N-lobe and C-lobe.Submitted March 8, 2012, and accepted for publication May 29, 2012.
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states in the free kinases are not fully understood. In addi-
tion, it is of great interest to determine what drives different
classes of inhibitors to bind to different DFG conforma-
tions. Discovering kinase inhibitors that target a particular
kinase has been an important goal in structure-based drug
design (3).
A protein kinase of interest as a drug target is p38a
mitogen-activated protein kinase (MAPK), a serine-threo-
nine kinase. The p38 MAPKs play a crucial role in regu-
lating the production of proinflammatory cytokines. The
enzymes have four isoforms and are drug targets for treat-
ing various inflammatory diseases, including rheumatoid
arthritis, asthma, and cardiovascular disease (4). Several
compounds can inhibit p38a MAPK in the nanomolar
range, and rich structure data have revealed a range of
various inhibitor binding modes with different DFG motif
conformations (5). NMR studies have also used p38a as
a model to study the DFG-in and DFG-out equilibrium.
To speed the discovery of new drugs, we need methods
that will enable us to accurately compute thermodynamic
differences between different states of a molecular system.
Computational methods can help shed light on these issues.
Molecular-dynamics and Monte Carlo methods with ex-
plicit waters are alternative methods to study protein
dynamics (6–10). Such methods can also be used to study
free-energy pathways, such as free-energy perturbation
(FEP) and thermodynamic integration (TI), to compute the
absolute or relative work of binding ligands to a protein
(11–18). However, such approaches tend to be too computa-
tionally demanding for routine use in drug-design projects,
and may be impractical for studying molecular systems that
undergo considerable conformational changes. At the otherdoi: 10.1016/j.bpj.2012.05.046
FIGURE 1 Overall view of the p38a structure. (a) Two inhibitors,
SB218655 (red) and urea 16 (blue), bind to p38a. The flexible and rigid
sets are shown in yellow and green, respectively. (b) The activation loop
can adopt both DFG-in (red, PDB 1a9u) and DFG-out (blue, PDB 1w82)
states for ligand binding.
Free-Energy Calculations: Protein Conformations, Ligand Binding 343end of the spectrum are the simplest and most efficient dock-
ing methods, which search for the single most stable ligand-
binding mode in a protein pocket and estimate binding
affinity with a scoring function (19–22). These fast methods
can rapidly screen large compound databases but typically
oversimplify binding. Endpoint free-energy methods, such
as molecular mechanics Poisson-Boltzmann/surface area
(MM/PBSA) and linear interaction energy (LIE) (23–29),
are middle-of-the-road, relatively fast methods as compared
with primer extension FEP or TI, but are more accurate and
provide greater physical details than molecular docking
methods.
In this study, we used the M2 algorithm to characterize
the DFG motif equilibrium of free p38a, and changes
in ligand and protein conformations with protein-inhibitor
binding. In addition, we aimed to reveal energetic and
entropic components that are important in ligand binding
and compute the overall binding free energies by analyzing
the association of various p38a inhibitors. M2 is an endpoint
method that one can use to approximate the overall free
energy of a molecular system by identifying a manageable
set of conformations (local energy minima) and summing
the computed configuration integral of each energy mini-
mum (30,31). The binding free energies computed with
M2 have shown encouraging agreement with experimental
data in chemical host-guest systems (32,33). Here, we com-
puted the conformational free energy of apo p38a and
binding free energy of various type I and II p38a inhibitors
using an optimal version of M2 for protein-ligand affinity
calculation (34). The 30 inhibitors included a few sets of
analogs with unavailable cocrystal structures (see Fig. S1
in the Supporting Material). The results accurately estimate
the absolute binding free energy and capture many details
about the physics that may be useful for understandingmolecular recognition and designing inhibitors to enhance
binding or specificity. Of note, our calculations also re-
vealed the DFG-in and DFG-out conformations of free
p38a, forces that stabilize different states, and the role of
the conserved DFG glycine.METHODS
Calculations with mining minima
As previously described (33,34), the second-generation mining minima
method, M2, computes the standard free energy of a molecular system,
such as a protein-ligand complex (PL), a free protein (P), or a free ligand
(L). The standard binding free energy can be calculated as follows:
DGo ¼ GoPL  GoP  G0L [1]
The standard free energy of each molecule (GX
o) is calculated by a sum of
contributions from N local wells i:
GoX ¼ RT ln
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where Goi and zi are respectively the standard free energy and the local
configuration integral from distinct energy wells. Other details are provided
in the Supporting Material Text1.
M2 is thus an endpoint method, because we only consider the free and
final bound states of a molecular system without including the intermediate
states during binding processes in Eq. 1. In brief, M2 consists of two parts:
1), an aggressive conformational search for distinct low-energy wells; and
2), an enhanced harmonic approximation for computing the configuration
integral zi of each well i. Both parts involve the Hessian matrix with
respect to bond-angle-torsion coordinates, and our harmonic approximation
accounts for anharmonicity of eigenvectors of the Hessian matrix with
eigenvalues < 2 kcal/mol/A˚ or 2 kcal/mol/rad. The correlation between
different degrees of freedom (e.g., multiple dihedrals may rotate in concert
or move with ligand translation/rotation) is captured in the Hessian matrix.
The free energy,GX
, of a molecule or complex, X¼ P, L, orPL, is estimated
by summing the local configuration integral zi from distinct energy wells
(conformations), as shown in Eq. 2. The probability of well i can be approx-
imated on the basis of zi, and thus the mean potential energy<U> or solva-
tion energy <W> can be obtained. The configurational entropy at standard
concentration can be computed as -TSconfig
 ¼G <UþW>. Note that the
configurational entropy includes both a conformational part, which reflects
the number of energy wells (conformations), and a vibrational part, which
reflects the average width of the energy wells.
We used the VM2 package for the calculation, and performed two itera-
tions for each ligand and four to 29 iterations for the free p38a and the
complexes until the accumulated free energy converged (see Table S1
and Fig. S2 for details) (32,34). For a typical ligand-protein complex, it
may take 12–14 h to finish one iteration using four cores of an Intel
Xeon 2.4 GHz CPU. We removed any duplicated conformations before
computing the final free energy. To reduce the computational cost, the
program allows a user-defined region of the protein to be held rigid with
flexibility of only a predefined binding-site region. All ligands are also flex-
ible and can freely translate and rotate within the binding site without
restraint. The rigid and flexible parts of p38a are the same for all systems,
so we chose residues within 7 A˚ for all ligands and atoms on the activationBiophysical Journal 103(2) 342–351
344 Huang et al.and glycine-rich loop as the flexible set (903 atoms included). The rigid set
contained the residues within 5 A˚ of the flexible set (1666 atoms included;
Fig. 1 a and Table S2), and the structure was the same in each calculation
for the complexes and the free protein. Other atoms not included in these
two sets were not considered during the M2 calculations.Structure preparation and parameters
The initial structure of our p38a template was drawn from the crystal struc-
ture with PDB code 1a9u because it is a wild-type human p38a with no
missing residues (35). The template shows a DFG-in conformation and
a cocrystal structure with a ligand SB203580. A couple of DFG-out protein
conformations were also provided as an initial structure, and the coordi-
nates of the activation loop were taken from complex structures with
a DFG-out protein conformation (PDB 1w82, 1w83, and 1wbv) to replace
that in the template (36). After substituting the activation loop with a DFG-
out conformation, we carried out a quick 100-step energy minimization
with the flexible region of p38a by using the Amber10 package (37). The
VM2 package was then used for further setup and free-energy calculations.
The initial structures of the ligands were obtained by their cocrystal struc-
tures with p38a or were constructed with the use of Macromodel if crystal
structures were not available. The Amber 99SB force field was used for
proteins. The general amber force field (GAFF) for ligands was used for
all systems. The final free energy considers the PBSA model, as described
previously (34,38). Other details regarding the computation setup are
provided in the Supporting Material Text2. All figure images were prepared
with the use of VMD (39).FIGURE 2 Sampled conformations of free DFG-in and DFG-out p38a.
(A1 and A2) Overview of DFG-in and DFG-out conformations, respec-
tively. The crystal structure is in blue (see Fig. 1 for PDB codes), the
sampled conformation with the lowest free energy is in red, and conforma-
tions with energies within 10RT above the global energy minimum are in
pink. (B1) Phe-169 (bond form) is buried in the hydrophobic cluster in
a DFG-in complex and the activation loop is exposed to the solvent (colored
thin line). The red and light blue tubes represent DFG-in and DFG-out
conformations, respectively. (B2) Side-chain arrangements in the DFG-
out state. Key interactions between important atom pairs are shown by
the pink dashed line. The light red and blue tubes represent DFG-in and
DFG-out conformations, respectively.RESULTS AND DISCUSSION
Sampling of DFG-in and DFG-out conformations
in free p38a protein
The M2 calculations revealed that the DFG-in and DFG-out
conformations have similar computed free energies in apo
p38a MAPK. The conformational free energies suggest
that the two DFG positions have equal population, which
is in good agreement with the dynamic equilibrium model
suggested by NMR (5). The calculations include both ener-
getic and entropic components. We focused on the residues
around the ligand-binding site, glycine-rich loop, and
activation loop to speed up the calculations (see Table S2
for details). Although the DFG-in conformations show
~3.7 kcal/mol stronger attraction energies than the DFG-
out conformations, the attraction energy is compensated
for by the less-favorable configuration entropy, yielding
the same conformational free energies. Of note, the number
of distinct conformations was similar in both states, and thus
vibrational entropy plays a key role in governing the fluctu-
ation of the free protein. The activation loop stayed in one
major DFG-in conformation, except for small fluctuations
between residues 172 and 174 (Fig. 2 A1), where coordi-
nates are missing in human p38a x-ray structures (40,41).
The glycine-rich loop shows moderate flexibility in both
DFG-in and -out conformations, which is consistent with
the structure alignment results with multiple ligand-p38a
cocrystal structures. Interestingly, our calculations revealed
several remarkably different DFG-out conformations, but
comparatively more similar DFG-in conformations (Fig. 2,Biophysical Journal 103(2) 342–351A1 and A2). Because Thr-180 is unphosphorylated in crystal
structures in both DFG states, we kept it unphosphorylated
in our calculations, and possible changes in protein fluctua-
tion induced by phospho-Thr are not discussed in this
study. Additional conformational searches showed that
the Thr-180 positions of the most stable DFG-in and
DFG-out conformations are the same as those in the crystal
structures. Because our DFG-out loop conformations are
diverse, and no existing experimental structures can be
used for comparison, we computed the f and j angles of
Asp-168, and compared the angles with ligand-p38a cocrys-
tal structures to ensure that our DFG-out conformations
satisfied the consensus definition of the DFG-out structures
(Fig. S4).
FIGURE 3 Positions and motions of key residues in DFG-out p38a. (a)
Orange spheres: nonpolar spine residues; yellow spheres: nonpolar clusters
(Tyr-35 and Leu-171); blue spheres: Asp-168–Gly-170 H-bond pair.
(b and c) Low-energy conformations within 10RT of global energy
minimum from computed DFG-in (b) and DFG-out (c) free p38a. Note
that no H-bonds formed in the DFG-in state shown in b, and dashed lines
in c indicate the H-bond between Asp-168 and Gly-170. Tubes and bonds
in purple represent structures taken from PBD 1a9u (b) and 1w82 (c).
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equally stable, the major attraction forces that stabilize
them differ (Table 1). The DFG-in states show stronger
van der Waal attractions, and the DFG-out states have
more favorable charge attractions. These two terms
balanced well, so <UþW> has a similar value in both
states. However, the two major attractions may not compen-
sate perfectly during the conformational change processes,
which results in energy barriers between the two states.
This situation may explain why the NMR spectra showed
a slow exchange between the DFG-in and DFG-out confor-
mations (5). With the DFG-in conformation, the Phe-169 is
buried by a hydrophobic pocket, which forms stronger
nonpolar attractions than it does with the DFG-out con-
formation. The nonpolar spine residues Leu-86, Leu-75,
Phe-169, and His-148 also form a rigid and hydrophobic
stack (Fig. S5) (42). Polar residues in the activation
loops, such as Arg-173, Thr-175, Asp-176, and Asp-177,
expose the side chains to the solvent (Fig. 2 B1). However,
Lys-53, the polar residue that is important for catalysis,
forms a salt bridge with Glu-71 instead of exposing itself
to the solvent, which also creates a preorganized pocket
for ligand binding. In similarity to the DFG-in conforma-
tions, Lys-53 and Glu-71 also formed a stable salt bridge
in the DFG-out conformations we found. However, this
was a case of the residues in the activation loop being
attracted to each other rather than the side chains being
exposed to the solvent (Fig. 2 B2). Therefore, compared
with the DFG-in conformations, the DFG-out conforma-
tions yield stronger Columbic attractions.
Because of the structural changes of the activation loop,
a 180 flip of Phe-169 breaks the assembled nonpolar spine
residues. Nevertheless, Phe-169 interacts with a nearby
nonpolar residue, Leu-171, and Leu-171 further recruits
Tyr-35 of the glycine-rich loop to form another nonpolar
cluster to stabilize both activation and glycine-rich loops
(Fig. 2 B2). The two nonpolar clusters may play a crucial
role in stabilizing the DFG-out states. In addition, the
flipped DFG-out motif forms a stable hydrogen (H)-bond
between Asp-168 and Gly-170, but the H-bond cannot
be seen in all of the DFG-in conformations (Fig. 3). Of
note, the same pair of H-bonds was found in the ligand
and DFG-out cocrystal structures, but not in the ligand-
bound DFG-in p38a. The lack of side chain in glycine
avoids potential side-chain interactions with other residues,TABLE 1 Computed free energy, average potential, and solvation
DFG PDB Gcal <UþW> TS <UVal> <UVD
in 1a9u 1349.40 2712.99 1363.60 364.54 35
out 1w82 1349.38 2709.30 1359.91 380.43 34
combined 1349.80 2711.16 1361.36 372.40 350
Decomposed free energy, Gcal, from our calculations includes the average poten
Lennard-Jones energy<UVDW>, nonpolar solvation free energy<WNP>, Coulo
sents the sum of <UVDW> and <WNP>; <Eploar> represents the sum of <UCoallowing an efficient bipositional switch and formation of an
H-bond with Asp-168 to stabilize the DFG motif. Our find-
ings contrast with those obtained for PKA and other serine/
threonine kinases that form a Asp-168–Gly-170 H-bond in
known active DFG-in structures (42). However, the Asp-
168–Gly-170 H-bond in p38a further supports the impor-
tance of the conserved Gly-170, which may provide local
stability for the DFG motif in DFG-in or DFG-out confor-
mations in various kinases.Binding free-energy calculations
The computed binding free energies, DGcal, agree well with
experimental binding affinities, DGexp, for various types of
inhibitors that bind to p38a with different conformations
of the DFG motif (Table 2 and Fig. 4). This agreement vali-
dates the energy model used in this study and demonstrates
that our search algorithm found all important conformations
in the free and bound states of each ligand-p38a system.
Here, we report the absolute binding affinities, not their
related values. Binding modes similar to crystal structuresfree energy (kcal/mol) of free p38a
W> <WNP> <Enp> <UCoul> <WPB> <Epolar>
8.22 45.55 312.67 2126.98 1445.39 3572.37
3.49 47.21 296.28 2244.37 1356.58 3600.95
.93 46.37 304.56 2185.06 1401.45 3586.51
tial energy <UþW>, configurational entropy TS, bonded terms <Uval>,
mbic energy<UCoul>, and PB solvation free energy<WPB>.<Enp> repre-
ul> and <WPB>.
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TABLE 2 Binding free energy, average binding potential energy, and solvation free energy (kcal/mol) of p38a inhibitors
Ligand name DFG PDB DGexp DGcal D(UþW) TDS DUVal DUVDW DWNP DEnp DUCoul DWPB DEpolar
Quinolinone 3 in 1ove 12.6 14.00 34.25 20.25 11.44 51.46 5.46 56.92 56.31 65.76 9.44
Quinazolinone 2-(a) in 1m7q_ang 12.23 14.28 37.06 22.78 9.79 44.40 5.34 49.74 49.34 50.44 1.10
Quinazolinone 2 in 1m7q 11.86 14.29 37.95 23.67 12.02 38.09 5.27 43.36 93.30 84.90 8.39
Pyridol-pyrimidine 4 in 1ouy 11.56 11.98 30.66 18.68 5.90 50.08 5.12 55.20 25.16 42.00 16.84
SB218655 in 1bmk 10.50 9.79 32.46 22.68 7.71 35.20 4.26 39.47 76.10 73.61 2.49
SB203580 in 1a9u 10.11 10.17 31.23 21.06 10.72 33.85 4.35 38.20 7.34 12.88 5.53
SB216995 in 1bl6 9.39 9.21 28.60 19.39 2.26 36.34 4.02 40.36 37.12 49.35 12.23
CHEBI:139669 in 1di9 7.32 6.25 18.89 12.65 4.06 37.65 4.15 41.80 9.43 34.61 25.18
CHEBI:139669-(a) in 1di9_ang 7.18 6.06 16.38 10.32 6.78 35.59 3.57 39.15 12.33 15.44 27.77
Indole 2 in 1w84 6.16 5.35 24.66 19.30 3.39 30.59 3.59 34.18 26.91 31.26 4.35
Pyridine 5 in 1wbw 6.02 6.12 22.57 16.45 2.21 36.25 3.75 40.00 18.21 36.07 17.86
Pyridine 1-(a) in 1w7h_ang 5.47 5.97 20.30 14.34 0.46 33.05 3.43 36.47 20.98 34.91 13.93
Pyridine 1 in 1w7h 3.99 3.67 16.23 12.57 5.22 32.33 3.18 35.50 35.69 47.95 12.26
BIRB-796 out 1kv2 10.70 10.57 36.67 26.08 5.50 61.09 6.84 67.93 13.80 37.76 23.96
SB203580 out 3gcp 10.11 10.43 27.83 17.38 0.26 45.66 5.16 50.82 19.19 40.66 21.47
Pyridine 9 out 1w83 9.70 11.00 34.03 23.02 1.68 50.21 4.83 55.05 15.53 2.01 17.54
Pyrazolourea 1 out 3hv7 9.35 10.27 35.71 25.42 9.35 48.90 5.34 54.24 41.26 48.65 7.39
Urea 16 out 1w82 9.27 8.71 27.98 19.25 2.84 47.95 5.06 53.01 20.82 0.42 20.40
CHEBI:679695-(a) out 3hv4_ang 9.17 9.18 34.26 25.07 15.75 56.71 6.13 62.84 8.93 19.96 11.03
CHEBI:679695 out 3hv4 8.99 8.40 32.75 24.34 10.58 57.95 6.21 64.16 0.79 19.82 19.04
Indole 24 out 1wbt 8.94 9.36 30.11 20.74 1.39 59.55 5.72 65.26 9.57 22.40 31.97
Pyridine 10 out 1wbn 8.92 7.02 32.74 25.71 17.35 47.83 5.45 53.28 5.36 6.76 1.40
Indole 23 out 1wbs 8.57 8.59 26.45 17.84 1.68 52.69 4.36 57.04 26.17 4.32 30.49
Pyrazolourea 1-(a) out 3hv7_ang 8.52 9.38 31.99 22.60 9.74 47.31 5.16 52.46 3.81 5.13 8.94
Pyrazolourea 1-(b) out 3hv7_ang 8.13 9.15 28.71 19.55 5.99 48.19 5.24 53.44 12.35 4.60 16.95
Pyrazolourea 1-(c)* out 3hv6 7.79 7.27 30.44 23.16 8.03 60.91 6.67 67.59 31.89 59.21 27.32
Diaryl urea 1 out 1kv1 7.22 8.23 25.47 17.22 6.62 41.74 4.29 46.03 6.78 18.94 12.16
Pyrazolourea 1-(d) out 3hv7_ang 6.60 6.57 20.94 14.34 15.98 44.74 4.57 49.31 17.81 28.41 10.61
indole 22 out 1wbv 5.24 5.36 21.58 16.20 3.77 44.92 3.46 48.38 18.02 10.76 28.78
Pyrazolourea 1-(e) out 3hv7_ang nb 1.53 28.39 26.84 8.17 42.82 5.58 48.40 7.51 17.56 10.05
Notations as in Table 1. The binding free energy was computed by DGcal¼Gcomplex-Gfree protein combine-Gfree ligand. Each decomposed energy is obtained by
DEDFG-in¼EDFG-in complex-EDFG-in free protein-EDFG-in free ligand and DEDFG-out¼EDFG-out complex-EDFG-out free protein-EDFG-out free ligand. The binding free energy
from experimental results is shown as DGexp. The PDB labeled as XXX_ang is the analog from XXX.
*The ligand, pyrazolourea 1-(c), is also called CHEBI:266984.
346 Huang et al.can also be found in our calculations. In addition to a single
ligand-binding mode available with experiments, our calcu-
lations provide details concerning all possible stable ligand-FIGURE 4 Calculated versus experimental binding free energies (kcal/
mol) for p38a inhibitors.
Biophysical Journal 103(2) 342–351binding modes in the protein-binding site, ligand and protein
conformational changes in their free and bound states, and
driving forces, including energetic and entropic components
(see examples in the Supporting Material Text3).
Because our free-energy calculations suggest that both
DFG states are equally stable, and experiments showed
slow equilibrium (kHz) versus faster association rate
constants (>104/Ms), we propose that p38a inhibitors com-
monly bind to a preorganized DFG-in or DFG-out con-
formation (5). This assumption is further supported by
previous surface plasmon resonance measurements that
showed that the kinetics of binding were largely unaffected
by the bound kinase conformation (43). Therefore, induced
conformational changes of the DFG loop by inhibitors are
not discussed here. To more appropriately reveal the driving
forces for ligand binding to a preorganized DFG motif, we
separated the two DFG forms (Table 2). For possible
induced DFG flipping during the binding processes, we
computed the energy changes (Table S5) but did not address
the driving forces in these cases. Determining whether any
term is significantly different to distinguish DFG-in and
DFG-out inhibitors is of interest. Because the configuration
FIGURE 5 Complex conformations of SB203580 and p38a with both
DFG-in and DFG-out conformations. (a) Sampled ligand-binding modes
(colored bond), DFG-in (red), and DFG-out (blue) conformations, which
illustrate space for interconverting the activation loop. (b) Low-energy
conformations within 10RT of the global energy minimum from the calcu-
lations, showing the fluctuation of Phe-169 in the DFG-out state and the
highly flexible methylsulfinylphenyl group. Sampled DFG-in and DFG-
out conformations are red and blue, respectively, and structures from
PDB IDs 1a9u and 3gcp are orange and black, respectively. (c) The sampled
activation loop and Phe-169 in both DFG-in and DFG-out conformations
are in cyan; crystal structures with PDB IDs, 3hv7, 1w82, 3gcp, and 1a9u
are in purple, yellow, black, and orange, respectively. Note that the structure
in complex with SB203580 from PDB 3gcp is the Cys-172 mutant (black
arrow) and shows different conformation (black) from our samples and
other experimental structures.
Free-Energy Calculations: Protein Conformations, Ligand Binding 347entropy is larger in DFG-out than DFG-in conformations in
apo p38a, if binding an inhibitor brings both complexes to
similar flexibility, are more notable entropy loss might be
expected in DFG-out binders. However, our calculations
revealed no general trend of configuration entropy loss for
DFG-in versus DFG-out inhibitors, as previously indicated
by experimental thermodynamic data (5). For both types
of inhibitors, in general, tight binders show a larger entropy
loss that is compensated for by stronger attraction forces
(Table 2). Of note, the values of our entropy changes cannot
be directly compared with experimental data because this
term reports conformational and vibrational entropy of
molecules but no solvent entropy. The M2 calculations
generated more distinct conformations of most free DFG-
out ligands within 1.8 kcal/mol (3RT) of the most stable
free conformer, which may due to the larger DFG-out
ligands selected (Table S4). Although dropping ligand
conformers in the bound state plays a role in the entropy
loss, the main contribution is from dihedral vibration. Inter-
estingly, ligands of similar size and with the same number of
rotatable bonds can generate quite different numbers of
stable low conformations in their free forms. For example,
both quinolinone 3 and quinazolinone 2 ligands have three
rotatable bonds and similar size but 17 and 57 low-energy
conformations, respectively (Table S5 and Fig. S1). In addi-
tion, inhibitors show considerably different conformations
in their free and bound states. Therefore, assuming that
the most stable conformation in the inhibitor’s free form is
also the most stable in the bound state may produce errors
in modeling.
In general, nonpolar interactions with the protein are
stronger with DFG-out than with DFG-in ligands because
the DFG-out inhibitors can contact with residues such as
Leu-74, Leu-75, Ile-84, Leu-86, Leu-104, and Leu-167 in
the hydrophobic cluster, and the compounds are usually
larger. Although they are in a hydrophobic environment,
the side chains of nonpolar residues may form multiple
alternative contacts with neighboring nonpolar residues
and provide a fluid-like interface (44), and the side chains
in the hydrophobic cluster show only a few dominant con-
formers in the low-energy structures (Fig. S7). The side-
chain conformations remain in their major rotameric states
in the complex conformations, with few induced side-chain
conformations in the hydrophobic cluster. Therefore, one
could select the most populated side-chain conforma-
tions when performing in silico compound screening with
molecular docking. The DFG-in inhibitors demonstrate
more favorable Columbic attractions. Although this term
is mostly compensated for by the desolvation penalty, the
DFG-in ligands still show stronger polar interactions than
the DFG-out ligands in most cases. The Asp-168 in the
DFG motif plays a role in interacting with the DFG-in inhib-
itors, but such interactions are completely diminished in the
DFG-out ligand-protein complexes.SB203580 binding to both DFG-in and -out
conformations
Although most inhibitors bind to DFG-in or DFG-out
conformations, and the ligand-p38a interactions lock
the DFG-in/DFG-out interconversion, a special inhibitor,
SB203580, can bind to both conformations. Our binding
free-energy calculations illustrated that the SB203580 com-
pound binds equally well to both DFG-in and DFG-
out states with a standard free energy of 10.17 and
10.43 kcal/mol, respectively. NMR revealed an equal pop-
ulation of both binding positions (5). The computed DG that
considers SB203580 binding to both DFG conformations
is ~10.32 kcal/mol, which also agrees well with experi-
mental measurements (10.11 kcal/mol (35)). In addition,
the calculations reveal that the positions of SB203580
in the binding pocket do not hinder the in/out exchange of
the DFG motif (Fig. 5 a). Our calculations easily reveal
the space organization that allows the interconversion
of the DFG motif, which is less clear in the crystal structure
(Fig. 5 c). Of note, the SB203580 and DFG-out cocrystal
structure (PDB 3gcp) has an A172C mutated residue (45).
The position of Cys-172 in the crystal structure differs
from that of other structures with wild-type Ala-172, andBiophysical Journal 103(2) 342–351
348 Huang et al.the subsequent loop structure is missing. Our calculations
involved the wild-type and full-length activation loop, and
the sampled conformations showed the same loop arrange-
ment as for other DFG-out cocrystal structures with tight
binders, such as compounds pyrazolourea 1 (PDB 3hv7)
and urea 16 (PDB 1w82; Fig. 5 c) (36,46).
Despite the motions of the DFG motif, SB203580 stays in
the same position in the binding pocket (Fig. 5). By
analyzing the ligand-binding modes, we can see that inhib-
itors that can target both conformations of the DFG motif
have the potential to enhance the binding affinities. The
pyridine and fluorophenyl rings contact nicely with p38a,
and the solvent-exposed methylsulfinylphenyl group is the
only functional group that significantly adjusts with
different DFG conformations (Fig. 5 b). Similarly to other
DFG-out ligands, Asp-168 moves toward the solvent and
breaks the charge interactions with the ligand, and Phe-
169, together with Tyr-35, generates nice nonpolar attrac-
tions with the ligand. These findings are reflected in Table
2, and SB203580 shows more negative van der Waal attrac-
tions for binding to the DFG-out than DFG-in conformation,
although the ligand does not have extensive contacts with
the hydrophobic cluster. In addition, Tyr-35 and Leu-171
form nice nonpolar contacts in free DFG-out conformations
that occlude the binding site. Therefore, significant rear-
rangements in Leu-171 and the glycine-rich loop open the
gate for SB203580 binding. This binding position reveals
the cross talk between the DFG motif and glycine-rich
loop, and the ligand may play a role in mediating the inter-
play of the two loops (45). In contrast, with free DFG-in
conformations, the two loops are open for the ligand, and
the easy-access binding site may contribute to a fast binding
of SB203580.FIGURE 6 Binding modes of pyrazolourea 1 and its analogs. (a) Stable
charge interactions among Glu-71 and Asp-168 (red) and the ligand (cyan).
(b) Global energy minimum found in the complex. The template pyrazo-
lourea 1 is shown as a colored bond. Gray, purple, yellow, orange, and green
represent the pyrazolourea 1 analogs (a), (b), (c), (d), and (e), respectively.
The charge interactions among Glu-71, Asp-168, and the inhibitors are rep-
resented as dashed lines. (c) Low-energy conformations within 10RT of the
global energy minimum of bound inhibitors. Each analog shows flexibility
in different function groups; however, changes in configurational entropy
upon binding cannot be easily predicted from looking at the ligand-binding
modes.Binding-affinities prediction for analogs
Ligand discovery processes involve the synthesis of many
analogs based on a lead compound to assess structure-
activity relationships. A series of analogs provide details
of molecular interactions to guide lead optimization, but
most analogs do not have cocrystal structures with the
protein. In this study we computed the binding free energies
of a few series of analogs with unavailable experimental
structures. All of the analogs studied here are also very
similar to their template compounds (e.g., quinazolinone
2, CHEBI:139669, Pyridine 1, pyrazolourea 1, and
CHEBI:679695 and their analogs (Fig. S1)). Because those
analogs are merely different from a functional group, the
predicted binding modes are similar to each other, as ex-
pected. For example, the unique naphthyl moiety of the pyr-
azolourea 1 compound locates in the hydrophobic cluster,
and the nitrogen and oxygen atoms of the urea group
show electrostatic attractions with Glu-71 and Asp-168.
Similarly, the benzene ring of the analog stays in the hydro-
phobic cluster, and the charge interactions between the ureaBiophysical Journal 103(2) 342–351group and p38a also hold (Fig. 6 b). However, because the
functional groups are not identical, the protein side chains
and ligand adjust to each other to optimize their interactions.
Of note, as compared with the free p38a with DFG-out
conformations, the loop of Ile-84 and Phe-169 rotate farther
to create a space for ligand binding. The positions of Phe-
169 in the complex conformations found with M2 are varied
and differ from those shown in crystal structures, which
suggests that the activation loop has high flexibility during
ligand binding.
The calculations can successfully distinguish small
differences in the analogs and reflect them in the free-energy
calculations (e.g., see the pyrazolourea analogs in Table S1).
Interestingly, the entropic term may play a crucial role in
successfully ranking the computed binding affinities, such
as in pyrazolourea 1 analogs. The worst binder in this series,
pyrazolourea 1-(e), retains attractive interaction energies as
compared with other analogs. However, the significantly
unfavorable entropy loss results in an extremely weak
binding free energy, which agrees with experiments (46).
Of note, the large entropic penalty cannot be easily observed
from the ligand binding modes (Fig. 6 c), which suggests
that detailed free-energy calculations are necessary for
accurate binding prediction. In addition, the individual ener-
getic terms offer more information about the driving forces
to further improve binding. For example, replacing the thi-
omethyl group (S-CH3) group by bromine in the
CHEBI:139669 analog reduces both polar and nonpolar
attractions. Because the data in Table 2 include changes in
Free-Energy Calculations: Protein Conformations, Ligand Binding 349intra- and intermolecular interactions, binding to different
ligands can sometimes yield different side-chain rearrange-
ments that noticeably change the intramolecular inter-
actions. For instance, quinazolinone 2 and its analog can
both form nice interactions with Thr-106, Met-109, and
Gly-110, and the difluorophenyl/chlorophenyl ring is
oriented into a hydrophobic environment. Nevertheless,
the small difference in the difluorophenyl and chlorophenyl
ring reorganizes the protein side chains nearby. As a result,
Asp-168 moves closer to the difluorophenyl ring and forms
an H-bond with Lys-53, which is not seen in either the free
p38a conformations or the complex with the chlorophenyl
ring analog (Fig. S8). The charge interactions yield con-
siderably more stable polar attractions in the complex
form in the quinazolinone 2 complex. Without considering
the energy changes from p38a, the changes in intermolec-
ular interactions are similar in both ligands.General comments on the method
Overall, the accuracy of our calculations is promising and
suggests that the method presented here will be broadly
useful for interpreting experimental studies of protein
conformations and ligand-protein binding. However, the
rigorous calculations are inevitably highly system-depen-
dent for the setup. Although our free-energy calculation
employs standard preparation steps as described in Mate-
rials and Methods, careful assessments and manual modifi-
cations are required to prepare the initial conformations. For
example, to speed up the calculations, only a predefined
binding-site region is flexible; thus, we need to be sure
that the rigid part has minimal changes in its free and bound
states. In addition, the computed Hessian matrix is very
memory-demanding and we used computers with 4GB
RAM; thus, the flexible region is set to be <1330 atoms.
Proper selection of flexible residues is very important
because the conformational flexibility can significantly
affect the accuracy of computing configuration entropy. In
this study, we analyzed >100 crystal structures of this
system to select the flexible region and our template struc-
tures. For other systems with only a handful of experimental
structures, other simulation tools, such as molecular-
dynamics simulations, may be performed to select the
flexible parts. To sample low-energy conformations for the
ligand-protein complexes more efficiently and thoroughly,
we did not rely solely on crystal structures. We selected
multiple apo p38a conformations found by our conforma-
tional free-energy calculations for the protein, and docked
inhibitors in the binding site to generate several initial
complex conformations.
Water molecules may play an important role in ligand
binding. All of the inhibitors chosen in this study do not
have bridging waters when they are forming a ligand-protein
complex. However, for systems with key bridging waters,
a hybrid implicit-explicit model should be used. In this studywe used the GAFF force field for ligands, and the force-field
parameters can reproduce the experimental structures of p38a
inhibitors in general. However, for a few ligands with unique
functional groups, we manually set the equilibrium values of
bond angles to be the same as thosemeasured in crystal struc-
tures, as detailed in the Supporting Material Text2 and
Fig. S2. For uncommon ligands without any experimental
reference structure, it may be necessary to test different force
fields, such as the OPLS and CHARMM force fields.CONCLUSIONS
Using p38a as a model system, we computed the confor-
mational and binding free energies of the free protein of
p38a and various p38a inhibitors using the M2 algorithm.
Because of the large-scale motions and flexibility of the
loop regions, it is experimentally challenging to obtain the
structures of free kinases. Our computational work success-
fully sampled multiple conformations of both DFG-in and
DFG-out states of free wild-type human p38a and revealed
the conformational fluctuations of the activation loop,
glycine-rich loop, and DFG motif. The free-energy calcula-
tions showed that both DFG-in and -out states are equally
populated in free p38a, which agrees with NMR results.
In addition, we suggest that potential interactions and the
conserved Phe-169 and Gly-170 have a role in stabilizing
both states. The calculations also indicate that the vibra-
tional entropy, not just the number of distinct confor-
mations, plays an important role in the conformational
ensemble. Further use of the M2 method may identify inter-
mediate states during the DFG flip, and provide a more
complete picture of pathways and free-energy barriers for
switching kinase activation and inactivation.
Our results also demonstrate the high predictive power of
binding affinities for analogs that lack experimental struc-
tures. As noted in previous theoretical studies for other
systems, the net free-energy changes are balances of notably
larger energy and entropy contributions (32,33,44). In
addition to providing overall binding free energies, our
calculations illustrate key differences in energetic and
configurational entropic terms when a protein and inhibitor
are in their free and bound states, which should be useful for
designing structure-based inhibitors. Finally, the computa-
tional work can help elucidate experimental observations.
For example, examination of the bound complex of the
inhibitor SB203580 revealed how ligand binding does not
affect flipping of the DFG motif.SUPPORTING MATERIAL
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